Year-end Sale % OFF 
Abstract
The article presents the results of in-depth interviews with key biotechnology executives and emphasizes the issues and challenges American investors face when investing venture capital funds in the Canadian biotechnology sector. The results show that, although capital suppliers feel that the quality of Canadian science is credible and that its biotechnology industry presents interesting investment opportunities, they must be careful to adjust their due diligence procedures to account for the specific characteristics of the Canadian environment. It is argued that specialized U.S. venture capital investors can capitalize on the sectorņs opportunities as long as the key issues are properly addressed.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
